Two people familiar with the plan tell AP it would let pharmacies compound popular peptides like BPC-157 without FDA enforcement, despite agency scientists' safety concerns.
Recap by typeshit. Full story at ABC News - Breaking News, Latest News and Videos.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
Researchers found women who had used hormonal birth control were more likely to go on to begin semaglutide than women who never had.
RAPS's weekly FDA roundup covers the citizen petition, new warning letters for manufacturing and lab violations, and a bipartisan clinical trial bill.
Loading…